⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

October 14, 2022Frontiers in Molecular BiosciencesOpen Access

Involvement of shedding induced by ADAM17 on the nitric oxide pathway in hypertension

View Full Paper

Ask AI

Bookmark

Share

Why the study?

Little knowledge is available regarding the involvement of ADAM17 and the nitric oxide pathways in hypertension.

Design

Narrative review

Authors

VSVanessa Maria dos Santos MSMatheus Vinicius Barbosa da Silva TPTereza Cristina Monteiro Melo PrazeresUniversidade Federal do Maranhão

Discussion

Loading...

Member takes

Implication

May guide ADAM17-targeted hypertension therapies; leaves open validation in clinical trials.

Key Points

Key points are not available for this paper at this time.

Cite This Study

Santos et al. (2022) studied this question.

synapsesocial.com/papers/6a814e840fbd199afca8c2e8 https://doi.org/10.3389/fmolb.2022.1032177

View Full Paper

Ask AI

Bookmark

Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Involvement of Tumor Necrosis Factor-α in Angiotensin II–Mediated Effects on Salt Appetite, Hypertension, and Cardiac Hypertrophy2008 · 280 citations
2Angiotensin-(1-7)–Stimulated Nitric Oxide and Superoxide Release From Endothelial Cells2001 · 219 citations
3Selective and specific regulation of ectodomain shedding of angiotensin-converting enzyme 2 by tumor necrosis factor α-converting enzyme2009 · 69 citations
4Permissive role of nitric oxide in macula densa control of renin secretion2004 · 73 citations
5Naringenin inhibits NG‑nitro‑L‑arginine methyl ester‑induced hypertensive left ventricular hypertrophy by decreasing angiotensin‑converting enzyme 1 expression2018 · 29 citations